Management of Bisphosphonate Treatment in Clinical Practice

Seminars in Oncology

Volumn 34, Issue SUPPL. 4, 2007, Pages

  Aapro, Matti S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE LESION; BONE METASTASIS; BREAST CANCER; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FRACTURE; FUNCTIONAL INDEPENDENCE MEASURE; HUMAN; LUNG CANCER; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; PATIENT COMPLIANCE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; HEALTH EDUCATION; HUMANS; PHYSICIAN-PATIENT RELATIONS;

EID: 36549010498     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.10.002     Document Type: Article

References (27)

1. Coleman R.E. Bisphosphonates: Clinical experience. Oncologist 9 4 (2004) 14-27
2. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
3. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
4. Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 88 (2000) 1082-1090
5. Cook R.J., and Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 93 (2001) 534-538
6. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
7. Hirsh V., Harper P., Cook R., et al. Bone metastases from non-small cell lung cancer (NSCLC) result in meaningful skeletal morbidity within a patient's lifetime. J Thor Oncol 2 suppl (2007) S434 (abstr PD6-3-7)
8. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
9. Berenson J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719-3736
10. Kyle R.A., Yee G.C., Somerfield M.R., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 (2007) 2464-2472
11. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62 (2007) 148-152
12. Wengstrom Y., Aapro M., Leto di Priolo S., et al. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: A European study. Breast 16 (2007) 462-468
13. Fallowfield L., Atkins L., Catt S., et al. Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Ann Oncol 17 (2006) 205-210
14. Delea T., McKiernan J., Brandman J., et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 4 (2006) 341-347
15. Delea T.E., McKiernan J.M., Liss M., et al. Impact of skeletal complications on total medical care costs in lung cancer patients with bone metastases. Proc Am Soc Clin Oncol 22 (2004) 533 (abstr 6064)
16. McKiernan J.M., Delea T.E., Liss M., et al. Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. Proc Am Soc Clin Oncol 22 (2004) 531 (abstr 6057)
17. Botteman M., Barghout V., Stephens J., et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 17 (2006) 1072-1082
18. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 4 (2004) 28-37
19. Silverman S., Siris E., Abbott T., et al. Adherence to bisphosphonate therapy is associated with decreased nonvertebral osteoporotic fracture risk (2005) Presented at the 27th Annual Meeting of the American Society for Bone and Mineral Research, Nashville, TN, September 23-27, (abstr SU417)
20. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
21. Mangiapane S., Hoer A., Gothe H., et al. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. J Clin Oncol 24 (2006) 698s (abstr 16823)
22. Weinfurt K.P., Li Y., Castel L.D., et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16 (2005) 579-584
23. Poor G., Atkinson E.J., O'Fallon W.M., et al. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 319 (1995) 260-265
24. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
25. Cleeland C.S., and Ryan K.M. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23 (1994) 129-138
26. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208
27. Chow E., Harris K., Tharmalingam S., et al. Early phase in the development of a bone metastases quality of life module. Clin Oncol 19 suppl (2007) S26 (abstr)